All News

RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
SI AS SpA ACR

Individualized Therapy in Ankylosing Spondylitis

MedPage Today

Whether patients with ankylosing spondylitis (AS) would improve substantially with tumor necrosis factor (TNF) inhibitor therapy was predicted with moderate to high accuracy based only on a standard lab test and two measures of disease activity, researchers reported from a modeling study.

Read Article
ankylosing%20spondylitis.jpg

Predicting Spondylitis in At-Risk Relatives

Jack Cush, MD

The risk of developing axial spondyloarthritis (axSpA) if you’re a first-degree relative (FDRs) of an ankylosing spondylitis (AS) patient has been deflined by a 35 year follow-up study showing that if you are a FDR of axSpA you may be at higher risk of acute anterior uveitis (AAU).

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Dr. Philip Mease on the importance of recognizing fibromyalgia, especially concurrently with rheumatic diseases FM does impact disease severity, esp in RA and AS @RheumNow #RNL2022 https://t.co/cGFYYdf6GU
Robert B Chao, MD doctorRBC ( View Tweet)
Less diversity ▶️ worse disease activity in Axial SpA!! Jose Scher @RheumNow #Rnl2022 https://t.co/HwwceaKW6M
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Microbiome and Autoimmunity, insightful!! by Jose Scher 👏👏 ▶️Effect of Bacterial METABOLITES through SCFA. ▶️Dysbiosis can lead to Autoimmunity. ▶️Dysbiosis affect medications response . Jose Scher @RheumNow #Rnl2022 https://t.co/oM7eM9hXEO
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#PsA axSpA Juvenile SpA great session @RheumNow #RNL2022. Lectures from gut microbiome to diff between #ankylosing #spondylitis vs axSpA to kid onset SpA. Lots of drugs coming to help out pts. https://t.co/IE8AlHS6hu
Janet Pope Janetbirdope ( View Tweet)
Dr. Pamela Weiss on Juvenile SpA 10-20% of AS pts have symptom once before 18 Only 38% of patients complained of back pain @RheumNow #RNL2022 https://t.co/Ydd58g7V62
Robert B Chao, MD doctorRBC ( View Tweet)
Difference between Juvenile versus adult onset SpA. Pamela Weiss @RheumNow #Rnl2022 https://t.co/WPO673jQi3
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Jose Scher on gut microbiome in spondyloarthritis Decreased diversity in AxSpA gut microbiome associated with worse disease activity Decreased diversity in PsA gut microbiome resembles IBD dysbiosis @RheumNow #RNL2022 https://t.co/30ntxPRSif
Robert B Chao, MD doctorRBC ( View Tweet)
High fiber diet can increase short chain fatty acids and decreased pro-arthritogenic cytokines @RheumNow #RNL2022 https://t.co/L1NQoSAAWS
Robert B Chao, MD doctorRBC ( View Tweet)
A dilemma at the ‘SPA’ what to use in axial PsA beyond TNFi? IL17, JAKi, Another TNFi. What about IL23i? #RNL2022 @RheumNow presented by Phil Mease https://t.co/Db68lqCEfJ
Janet Pope Janetbirdope ( View Tweet)
ClinicalPearl Juvenile SpA is Impt as Pam Weiss states #RNL2022 @RheumNow Kids esp teen boys do get axSpA and Juvenile isn’t AS https://t.co/aEqCBsOLPB
Janet Pope Janetbirdope ( View Tweet)
ICYMI: anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/6MQ3CMU7YG https://t.co/okl2e1Q6Hs

Links:

Dr. John Cush RheumNow ( View Tweet)
anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS

Links:

Dr. John Cush RheumNow ( View Tweet)
Drug Survival Differences in RA, PsA, SpA and PsO https://t.co/aBRhTbVmCM https://t.co/ZDGiKlowoV

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Spondyloarthritis in Early Crohn's Disease Analysis of a German Crohn's disease cohort finds that in patients with early CD, SpA was present in nearly one out of five patients and was associated with HLA-B27 positivity and a highly active CD. https://t.co/ExAHSCw5v2 https://t.co/UDZHbg9ySY

Links:

Dr. John Cush RheumNow ( View Tweet)
2/28, was “Rare Disease Day” in the USA, w/many tributes to the patients, doctors & researchers dedicated to these disorders. Moreover, it was a great opportunity to shout about the many rare conditions that don’t get enough press, praise or funding. https://t.co/ft8Y8Mmdnz https://t.co/WqhRGzNRtS

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×